GSK pays $70M to extend its entry to Tempus affected person knowledge library

British multinational pharmaceutical and biotech firm GSK introduced a three-year settlement with a $70 million preliminary cost to broaden its entry to Tempus’ AI-powered knowledge library, together with its de-identified affected person knowledge. 

GSK says the collaboration will enable it to leverage the U.S.-based firm’s library to speed up drug discovery in oncology, enhance its scientific trial design, establish drug targets and pace up trial enrollment. 

After three years, GSK has the choice to increase the settlement for a further two years.  

The collaboration builds on GSK and Tempus’ present partnership centered on scientific trial enrollment of sufferers with particular most cancers sorts, permitting GSK to entry Tempus’ de-identified affected person knowledge particularly. 

The businesses are presently collaborating on an open-label part II examine, utilizing a data-driven method design to hurry up examine timelines. 

“This collaboration will present GSK with distinctive insights to find higher medicines and remodel drug discovery. Tempus enhances the work our crew is already doing on the intersection of genomics and machine studying throughout each early discovery and scientific trials,” Tony Wooden, chief scientific officer at GSK, mentioned in a press release.

THE LARGER TREND

GSK has partnered with quite a few firms previously 12 months to spice up its scientific analysis features.   

In April of this 12 months, GSK introduced a multi-year drug discovery partnership with AI-enabled pathology firm PathAI to advance scientific trials and drug improvement in oncology and for nonalcoholic steatohepatitis (NASH). 

Earlier this 12 months, GSK introduced it prolonged its drug discovery partnership with shopper genetics firm 23andMe till July 2023. That collaboration started in 2018 when GSK offered $300 million to the now publicly traded firm.

Final 12 months, GSK expanded its partnership with Viome Life Sciences, a maker of at-home checks for intestine and immune system well being. The alliance permits GSK to check the connection between the intestine microbiome and a few continual illnesses, like autoimmune issues.